Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 save search
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
Published: 2021-11-24 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 14515.38%
H: 0.0%
C: -1.95%
fda lung cancer phase 1 positive cancer phase 2
Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial
Published: 2022-05-12 (Crawled : 13:00) - biospace.com/
RMTI | $1.49 -2.61% -4.08% 54K
|
Health Technology
|
| O: 1157.14%
H: 2.03%
C: -32.56%
fda application trial home phase 2
First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
Published: 2023-06-13 (Crawled : 11:00) - globenewswire.com
FWBI | $3.02 -3.21% -2.63% 35
|
Manufacturing
|
| O: 150.48%
H: 4.89%
C: -46.85%
biopharma fibrosis adrulipase trial phase 2
UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
Published: 2022-08-11 (Crawled : 22:00) - globenewswire.com
UBX | $1.47 -1.34% -0.68% 82K
|
Health Technology
|
| O: 115.27%
H: 1.09%
C: -28.42%
ubx1325 study phase 2
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
PXMD | $0.692 -3.35% -2.24% 250K
|
Health Technology
|
| O: 93.77%
H: 73.6%
C: -23.86%
publication results study phase 2
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
Published: 2021-10-03 (Crawled : 00:00) - globenewswire.com
XENE | $39.5 -3.87% -4.13% 330K
|
Health Technology
|
| O: 69.5%
H: 22.03%
C: 18.82%
phase 2 results topline phase 2b trial conference
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
Published: 2021-09-20 (Crawled : 12:15) - biospace.com/
EDSA | $4.31 -3.47% -3.84% 4.9K
|
Health Technology
|
| O: 68.6%
H: 26.98%
C: 26.14%
covid phase 2 positive antibody biotech iot covid-19
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
Published: 2023-12-05 (Crawled : 12:30) - globenewswire.com
ALLR | $1.37 -3.52% -3.65% 4K
|
n/a
|
| O: 66.69%
H: 11.0%
C: -42.04%
drp diagnostic cancer women companion advanced phase 2
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
BBIO | $25.03 -1.69% -1.76% 1.5M
|
Health Technology
|
| O: 65.5%
H: 7.78%
C: -8.17%
velocity positive results achondroplasia phase 2
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
Published: 2023-04-24 (Crawled : 21:00) - globenewswire.com
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 63.83%
H: 12.66%
C: -32.14%
bx1000 trial results phase 2
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
Published: 2023-04-25 (Crawled : 13:20) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 63.83%
H: 12.66%
C: -32.14%
bx1000 positive trial results phase 2
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
ENTX | $2.07 -6.76% -7.25% 1.2K
|
Health Technology
|
| O: 60.58%
H: 20.39%
C: -9.85%
AMGN | News | $273.01 -0.19% -0.17% 400
|
Health Technology
|
| O: -0.11%
H: 0.04%
C: -0.39%
phase 2 topline eb613 dmd
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
Published: 2021-08-10 (Crawled : 13:00) - biospace.com/
FULC | $7.28 -2.15% -2.27% 350K
|
Health Technology
|
| O: 58.58%
H: 67.22%
C: 42.09%
disease phase 1 positive results trial phase 2 phase 3
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
VERU | $1.32 3.53% 3.77% 1.5M
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
results breast cancer cancer positive endocrine trial trial results phase 2 metastatic breast cancer
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
Published: 2021-06-16 (Crawled : 13:00) - biospace.com/
APRE | $5.17 -3.72% 6.3% 6.3K
|
Health Technology
|
| O: 50.72%
H: 6.7%
C: -26.4%
phase 1 trial phase 3 phase 2 aml
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
Published: 2022-10-07 (Crawled : 14:00) - globenewswire.com
GCAN | $0.0006 16.67% 110K
|
|
| O: 50.0%
H: 26.67%
C: -46.67%
application trial submission phase 2
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ONCT | $8.545 -2.51% -0.11% 1.6K
|
Health Technology
|
| O: 48.5%
H: 23.29%
C: 0.76%
phase 3 phase 1 phase 2
CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8:30am ET
Published: 2020-12-18 (Crawled : 15:00) - biospace.com/
CNSP | News | $0.214 1.91% -4.9% 4.4K
|
Health Technology
|
| O: 47.2%
H: 2.99%
C: -21.47%
approval fda berubicin trial phase 2 fda ide
Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis
Published: 2021-12-17 (Crawled : 14:00) - biospace.com/
BLPH | $0.0541 -7.68% -45.37% 15M
|
Health Technology
|
| O: 43.46%
H: 0.0%
C: 0.0%
inopulse treatment phase 2 hypertension pulmonary hypertension positive topline
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Published: 2022-06-10 (Crawled : 12:20) - biospace.com/
COGT | $6.54 -6.03% -6.34% 5
|
Health Technology
|
| O: 40.81%
H: 0.0%
C: 0.0%
ongoing trial positive phase 2
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.